Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma

Inclusion Criteria: * Histologically confirmed diagnosis of malignant melanoma. * Previously untreated and non-resectable disease * Measurable or evaluable tumour. * Age ≥ 18 and ≤ 75 years. * Performance status ECOG-WHO 0, 1 and 2 (Appendix III) * Written informed consent (Appendix II) * Adequate bone marrow liver, heart and renal function: * WBC count \>3.0 x 109/L and platelets count \>100 x 109/L. * ASAT, ALAT \<2 x upper normal laboratory value. * Serum creatinine \<2 x upper normal laboratory value. Exclusion Criteria: * Previous treatment with chemotherapy. * Clinical signs of brain metastases. * Severe cardiac insufficiency (NYHA III or IV) with uncontrolled and/or unstable cardiac or coronary artery disease. * Severe active infections such as HIV or hepatitis B or Hepatitis C. * Medication for severe intercurrent disease which might affect immunocompetence (e.g. immunosuppressants, systemic corticosteroids). * Pregnancy, breast-feeding or absence of adequate contraception for fertile patients. * Simultaneously participation in other clinical studies. * Any reason why, in the opinion of the investigator, the patient should not participate.